Emerging therapies for heart failure

Bibliography

• GHEORGHIADE M, BONOW RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation (1998) 97:282–289.
   PubMed Web of Science ®Google Scholar
• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the ACC/AHA task force on practice guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation (2001) 104:2996–3007.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive treatment guidelines andexcellent, up-to-date description of the clinical syndrome of HF from the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
   Google Scholar
• STEWART S, JENKINS A, BUCHAN Set al: The current cost of heart failure to the National Health Service in the UK. Ear. Heart Failure (2002) 4:361–371.
   PubMed Web of Science ®Google Scholar
• O'CONNELL JB: The economic burden of heart failure. Clin. Cardio] (2000) 23(Suppl. III): 1116–11110.
   Google Scholar
• STEWART S, MACINTYRE K, HOLE DJ, CAPEWELL S, MCMURRAY JJV: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur.j Heart Failure (2001) 3:315–322.
   PubMed Web of Science ®Google Scholar
• •Excellent article to increase understanding of the 'malignant' nature of an HF diagnosis compared to a cancer diagnosis.
   Google Scholar
• QUINN S, WILLIAMS G: Regulation of aldosterone secretion. Ann. Rev Physiol (1988) 50:409–426.
   PubMed Web of Science ®Google Scholar
• •Good basic review of the pathways involved in the control of aldosterone secretion from the adrenal gland.
   Google Scholar
• THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl. Med. (1997) 336:525–533.
   PubMed Web of Science ®Google Scholar
• MANN DL, KENT RL, PARSONS B, COOPER G IV: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation (1992) 85:790–804.
   PubMed Web of Science ®Google Scholar
• CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• HIALMARSON A, GOLDSTEIN S, FAGERBERT B et al.: Effect of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA (2000) 283:1295–1302.
   PubMed Web of Science ®Google Scholar
• PACKER M, COLUCCI WS, SACKNER-BERNSTEIN JD et al.: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate-to-severe heart failure. Circulation (1996) 94:2793–2799.
   PubMed Web of Science ®Google Scholar
• PACKER M, COATS AJS, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl. I Med (2001) 344:1651–1658.
   PubMed Web of Science ®Google Scholar
• BETA-BLOCKERS EVALUATION OF SURVIVAL TRIAL INVESTIGATORS: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl. Med. (2001) 344:1659–1667.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE ACUTE MYOCARDIAL INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with cinical evidence of heart failure. Lancet (1993) 342:821–828.
   PubMed Web of Science ®Google Scholar
• ISRAELLI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converging enzyme inhibition therapy: a review of the literature an pathophysiology. Ann. Intern. Med. (1992) 117:234–242.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-HERNANDEZ R, SOSA-CANACHE B, VELASCO M, ARMAS-HERNANDEZ MJ, ARMAS-PADILLA MC, CAMMARATA R: Angiotensin II receptor antagonists role in arterial hypertension. I Human Hyper. (2002) 16:S93–S99.
   PubMed Web of Science ®Google Scholar
• PITT, B, SEGAL R, MARTINEZ FA et al:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation fo Losartan in the Elderly Study, ELITE). Lancet (1997) 348: 747–752.
   Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survivial Study ELITE II. Lancet (2000) 355: 1582–1587.
   Google Scholar
• COHN JN, TOGNONI G: VALSARTAN HEART FAILURE TRIAL INVESTIGATORS: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Eng.J Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• MCKELVIE RS, YUSUF S, PERICAK D, AVEZUM A et al: THE RESOLVD PIOLOT STUDY INVESTIGATORS: Comparison of candesartan, enalapril and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation (1999) 100:1056-1064. Demonstration that 'aldosterone rebound' occurs in HF patients chronically treated with maximal doses of both ACE inhibitors and ARBs.
   PubMed Web of Science ®Google Scholar
• STAESSEN J, LIJNEN P, FAGARD R, VERSCHEUREN LJ, AMERY A: Rise in plasma concentrations of aldosterone during long-term angiotensin II suppression. Endo. (1981) 91:457–465.
   Web of Science ®Google Scholar
• CLELAND JG, DARGIE HJ, HODSMAN GP et al.: Captopril in heart failure: a double-blind controlled trial. Br. Heart (1984) 52:530–535.
   PubMedGoogle Scholar
• BARGHI C, BOSCHI S, AMBROSINI E et al.: Evidence of partial escape of RAA blockade in patients with acute MI treated with ACE inhibitors. I Clin. Pharm. (1993) 33:40–45.
   Google Scholar
• MACFADYEN RJ, LEE AF, MORTON JJ, PRINGLE SD, STRUTHERS AD: How often are angiotensin II and aldosterone raised during chronic ACE inhibitor treatment in chronic failure? Heart (1999) 82:57–61.
   PubMed Web of Science ®Google Scholar
• •Comprehensive discussion of how aldosterone levels 'rebound' in HF patients treated chronically with ACE inhibitors.
   Google Scholar
• LEE AF, MACFAYDEN RJ, STRUTHERS AD: Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eui: I Heart Failure (1999) 1:401–406.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, ENEROTH P, KJEKSHUS J, WILHELMSEN L: THE CONSENSUS TRIAL STUDY GROUP: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation (1990) 82:1730–1736.
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate a positive correlation between plasma aldosterone levels and mortality in HF patients.
   Google Scholar
• DUPREZ DA, BAUWENS FR, BUYZERE ML et al.: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am. Cardiol. (1993) 71:17A–20A.
   Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng]. I Med. (1999) 341:709-717. Landmark study demonstrating a significant mortality benefit with aldosterone blockade using spironolactone in late-stage HF patients.
   Google Scholar
• WEBER MA: Vasopeptidase inhibitors. Lancet (2001) 358:1535-1532. Excellent up-to-date review on vasopeptidase inhibitors currently in clinical development for hypertension and HE
   Google Scholar
• PACKER M: Omapatrilat versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Late Breaking Clinical Trials, American College of Cardiology Meeting, Atlanta (March 2002).
   Google Scholar
• SEED A, HILLIER C, BERRY C et al: Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Failure Rev (2001) 6:317–323.
   PubMedGoogle Scholar
• CODY RJ, HAAS GJ, BINKLEY PF et al.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation (1992) 85:504–509.
   PubMed Web of Science ®Google Scholar
• PACHER R, STANEK B, HOLSMANN M et al.: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. I Am. Coll Cardiol. (1996) 27:633–641.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, YOUNG JB, DURAND JB et al.: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with Class III to IV congestive heart failure. Circulation (2001) 103:973–980.
   PubMed Web of Science ®Google Scholar
• ELLAHHAM SH, CHARLON V, ABASSI Z: Bosentan and the endothelin system in congestive heart failure. Clin. Cardiol. (2000) 23:803–807.
   PubMed Web of Science ®Google Scholar
• PACKER M: Effects of the Endothelin Receptor Antagonist Bosentan on the Morbidity and Mortality in Patients with Chronic Heart Failure: Results of the ENABLE 1 and 2 Trial Program. Late Breaking Clinical Trials, American College of Cardiology Meeting, Atlanta (March 2002).
   Google Scholar
• SCHRIER RW, BERL T, ANDERSON RJ: Osmotic and nonosmotic control of vasopressin release. Am. I Physiol. (1979) 236:F321–F332.
   PubMed Web of Science ®Google Scholar
• FUKUZAWA J, HANEDA T, KIKUCHI: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Biochem. (1999) 195:93–98.
   Web of Science ®Google Scholar
• MULINARI RA, GAVRAS I, WANG YX et al.: Effects of vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction. Circulation (1990) (81):308–311.
   PubMed Web of Science ®Google Scholar
• YATSU T, TOMURA Y, TAHARA A et al.: Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin ViA and V2 receptor antagonist. Eur.j Pharmacol. (1999) 376:239–246.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V iA and V2 receptor antagonist, in patients with advanced heart failure. Circulation (2001) (1002417–2423.
   Google Scholar
• PALMIERI, EA, BIONDI, B, FAZIO S: Aldosterone receptor blockade in the management of heart failure. Heart Failure. Rev (2002) 7:205–219.
   PubMedGoogle Scholar
• PITT B, WILLIAMS G, REMME W: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone PostAMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. (2001) 15:79–87.
   PubMed Web of Science ®Google Scholar
• ••Detailed description of the EPHESUS trialdesign in which concept will be tested that selective aldosterone blockade (with eplerenone) will reduce mortality in post-MI HF patients.
   Google Scholar
• PFEFFER MA: New treasures from old? EPHESUS. Eplerenone PostAMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. (2001) 15:11–13.
   PubMed Web of Science ®Google Scholar
• SPERTUS JA, TOOLEY J, JONES P et al.: Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am. Heart j (2002) 143:636–642.
   PubMed Web of Science ®Google Scholar
• MCMAHON EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Can: Opin. Pharm. (2001) 1:190–196.
   PubMedGoogle Scholar
• •Recent summary of pathophysiological effects of aldosterone on the cardiovascular system and predinical data supporting development of the selective aldosterone blocker eplenerone.
   Google Scholar
• DELYANI JA, ROBINSON EL, RUDOLPH AE: Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am. Physiol. (2001) 50:H647–H654.
   Google Scholar
• PITT B, RONIKER B: Eplerenone, a novel selective aldosterone receptor antagonist (SARA): Dose finding study in patients with heart failure. I Am. Coll. Cardio. (1999) 33 (Suppl. A):188A–189A.
   Google Scholar
• TSUTAMOTO T, WADA A, MAEDA K et al.: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic pepetide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation (1997) 96:509–516.
   PubMed Web of Science ®Google Scholar
• •First study to link BNP levels and outcomes in patients with chronic HE
   Google Scholar
• TORRE-AMIONE G, KAPADIA S, BENEDICT C et al.: Pro-inflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). I Am. Coll. Cardiol. (1996) 27:1201–1206.
   PubMed Web of Science ®Google Scholar
• BRYANT D, BECKER L, RICHARDSON J et al.: Cardiac failure in transgenic mice with myocardial expression of tumour necrosis factor-a. Circulation (1998) 97:1375–1381.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, KRIBBS S, CLUBB FJ Jr et al.: Patholphysiologically relevant concentrations of tumour necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 97:1382–1391.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN M et al.: Results of targeted antitumour necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 103:1044–1047.
   PubMed Web of Science ®Google Scholar
• •Early Phase II results with ENBREL in patients with advanced HE
   Google Scholar
• MCMURRAY J, PFEFFER MA: New therapeutic options in congestive heart failure. Part II. Circulation (2002) 105:2223–2228.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, LI YY, MCTIERNAN CF: Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet (2001) 357:654–655.
   PubMed Web of Science ®Google Scholar
• PETERSON JT, HALLAK H, JOHNSON L et al.: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 103:2303–2309.
   PubMed Web of Science ®Google Scholar
• CHANCEY AL, BROWER GL, PETERSON JT, JANICKI JS: Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation (2002) 105:1983–1988.
   PubMed Web of Science ®Google Scholar
• SPINALE FG, COKER ML, KROMBACH SR et al.: Matrix metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Circ. Res. (1999) 85:364–376.
   PubMed Web of Science ®Google Scholar
• ••First evidence that inhibition of MMPs canreduce LV dilation in HE
   Google Scholar
• HAGEGE AA, VILQUIN JT, BRUNEVAL P MENASCHE: Regeneration of the myocardium. A new role in the treatment of ischemic heart disease? Hypertension (2001) 86:616–621.
   Google Scholar
• ••Excellent recent review on novel strategiesfor regenerating myocardium.
   Google Scholar
• JAIN M, DERSIMONIAN H, BRENNER DA et al.: Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation (2001) 103:1920–1927.
   PubMed Web of Science ®Google Scholar
• TAYLOR DA, ATKINS BZ, HUNGSPREUGS P: Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nature Med. (1998) 4:929–933.
   PubMed Web of Science ®Google Scholar
• CHIU RCJ, ZIBAITIS A, KAO RL: Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg. (1995) 60:12–18.
   PubMed Web of Science ®Google Scholar
• MENASCHE P, HAGEGE AA, SCORSIN M et al.: Myoblast transplantation for heart failure. Lancet (2001) 357:279–280.
   PubMed Web of Science ®Google Scholar
• ISNER JM: Myocardial gene therapy. Nature (2002) 415:234–239.
   PubMed Web of Science ®Google Scholar
• •Good update on myocardial gene therapy with emphasis on current challenges.
   Google Scholar
• GRIMES C: Adenovirus FGF angiogenic gene therapy (AGENT) trial. Presented at the Late-Breaking Clinical Trials session of 50th annual American College of Cardiology. Orlando, FL, 19th March 2001.
   Google Scholar
• MIYAMOTO M, DEL MONTE F, SCHMIDT U et al.: Adenoviral gene transfer of SERCA2a improves left ventricular function in aortic-banded rats in transition to heart failure. Proc. Nati Acad. Sci. USA (2000) 97:793–798.
   PubMed Web of Science ®Google Scholar
• HE H, MEYER M, MARTIN JL et al.: Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation (1999) 100:974–980.
   PubMed Web of Science ®Google Scholar
• MAURICE JP, HATA JA, SHAH AS et al.: Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary 132-adrenergic receptor gene delivery. J. Clio. Invest. (1999) 104:21–29.
   PubMed Web of Science ®Google Scholar
• OLIVETTI G, ABBI R, QUAINT F et al: Apoptosis in the failing human heart. N. Engl. J. Med. (1997) 336:1131–1141.
   PubMed Web of Science ®Google Scholar
• KIRSHENBAUM LA, DE MOISSAC D: The bc1-2 gene product prevents programmed cell death of ventricular myocytes. Circulation (1997) 96:1580–1585.
   PubMed Web of Science ®Google Scholar
• MATSUI T, LI L, DEL MONTE F et al: Adenoviral gene transfer of activated PI 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes M vitro. Circulation (1999) 100:2373–2379.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR: P-adrenergic receptor blockade in chronic heart failure: Circulation (2000) 101:558–569.
   PubMed Web of Science ®Google Scholar
• ••Excellent recent comprehensive review on13-blockers in HE
   Google Scholar
• PACKER M, O'CONNOR CM, GHALI JK et al.: Effect of amlodipine on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. 335:1107-1114.
   Google Scholar
• COHN JN, ZIESCHE S, SMITH R et al.: Effect of the calcium antagonist felodipine as supplementary vasodilatory therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 96:856–863.
   PubMed Web of Science ®Google Scholar
• LINDSEY ML, GANNON J, AIKAWA M et al: Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation (2002) 105:753–758.
   PubMed Web of Science ®Google Scholar
• HAAS TL, MADRI JA: Extracellular matrix-driving matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med. (1999) 9:70–77.
   PubMed Web of Science ®Google Scholar
• ZANNAD F, ALLA F, DOUSSET B, PEREZ A, PITT B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation (2000) 102:2700–2706.
   PubMed Web of Science ®Google Scholar
• SABBAH HN, SHIMOYAMA H, KONO T et al.: Effects of long-term monotherapy with enalapril, metoprolol and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation (1994) 89:2852–9.
   PubMed Web of Science ®Google Scholar
• SUZUKI G, MORITA H, SHAROV VG et al.: Blockade of aldosterone receptors with eplerenone prevents progressive left ventricular dysfunction and attenuates remodeling in dogs with heart failure. Presented at American Heart Association Meeting, Orlando, FL March 2001.
   Google Scholar
• ••Exciting new data in dog HF model thatsupports use of the selective aldosterone blocker eplenerone in HF patients.
   Google Scholar
• SHAH AS, WHITE DC, EMANI S et al: In vivo ventricular gene delivery of a 13-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation (2001) 103:1311–1316.
   PubMed Web of Science ®Google Scholar
• SEIDMAN JG, SEIDMAN C: The genetic basis for cardiac hypertrophy: from mutation identification to mechanistic paradigms. Cell (2001) 104:557–567.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the genetic basis for cardiomyopathies in man.
   Google Scholar